Development of small molecule therapeutics for mitigating opioid withdrawal syndrome
Active Project Grant Awarded Last action
- Award ID
- R44DA053844
- Recipient
-
Evodenovo Inc. UEI L17ZDJF2LJH1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,756,907
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 84% complete
- Place of performance
- Woburn, MA 01801, USA
Award details come from USAspending.gov.
Description
- Abstract
- The use of opioids for managing pain is widespread, but IT is plagued by several limitations, including the development of dependence, decreasing efficacy over time, and adverse somatic effects. Opioid use disorder (OUD) is a growing global health problem with a market size of $4.81 billion by 2028. The current standard of care involves using opioid replacement therapies such as methadone and buprenorphine, however, these treatments are associated with high rates of relapse and problematic side effects. All opioid drugs target the μ-opioid receptor (MOR) to produce both positive therapeutic results and negative side effects. Research conducted on the MOR has demonstrated the possibility of segregating its downstream signaling pathways to preserve pain relief while reducing the risks of dependence. However, achieving that goal solely by targeting MOR is challenging. Evodenovo founders uncovered a g protein-coupled receptor GPR139 with "anti-opioid" activity, which selectively separates the behavioral effects of opioids. This discovery has the potential to enhance opioid pain relief while reducing dependence, making IT a promising treatment for OUD. The project aims to develop small molecule compounds to treat OUD by targeting GPR139. Evodenovo assembled a multi-disciplinary team of wide ranging expertise in genetic neuronal models, gpcr signaling, medicinal chemistry and opioid pharmacology to pursue the following aims: 1) develop drug-like small molecule inhibitors of GPR139, 2) optimize lead compounds for modulation of opioid effects in endogenous neuronal systems, and 3) perform testing of GPR139 lead compounds for opioid effects in rodents. The overall goal of this project is to identify the most promising compounds that can effectively reduce opioid dependence in mouse models. The following steps will involve obtaining IND designation, manufacturing, conducting clinical trials, and ultimately gaining approval from the FDA. This will enable the commercialization of a pioneering therapeutic solution for the treatment of opioid use disorder (OUD). Evodenovo RFA-DA-23-021/ PI: SID a. Labed project summary - page 1 of 1
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $687,310 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,094,320 | |
| Amendment | $1,094,320 | |
| Original award | $880,957 |
Quick answers
Who received award R44DA053844?
R44DA053844 was awarded to Evodenovo Inc. by National Institute on Drug Abuse (National Institutes of Health) on April 15, 2022.
How much is award R44DA053844 worth?
$3,756,907 has been obligated on R44DA053844.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award